Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 403 of 1,261
  1. US 10751339

    Substituted aminopyrimidine compounds and methods of use

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  2. US 10751302

    Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  3. US 10751347

    Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy

    REGENERA PHARMA LTD. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  4. US 10751348

    Formulations of testosterone and methods of treatment therewith

    The Board of Regents of the University of Texas System · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  5. US 10750943

    Imaging-guided creating and monitoring of retinal vascular occlusive disease

    Northwestern University · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  6. US 10752651

    Antimicrobial compounds, compositions, and uses thereof

    Lakewood Amedex, Inc. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  7. US 10752607

    Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  8. US 10752598

    Aryldiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  9. US 10752626

    Iso-citrate dehydrogenase (IDH) inhibitor

    SHANGHAI METON PHARMACEUTICAL CO., LTD · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  10. US 10752656

    Anti-microbial supramolecular structures

    Northwestern University · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  11. US 10752690

    Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  12. US 10752701

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  13. US 10752920

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  14. US 10751416

    IL-26 inhibitors

    The Board of Regents of the University of Texas System · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  15. US 10751533

    Regulation of autonomic control of bladder voiding after a complete spinal cord injury

    The Regents of the University of California · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  16. US 10751281

    Auris formulations for treating otic diseases and conditions

    The Regents of the University of California · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  17. US 10751343

    Nasal compositions stimulating ciliary activity

    Veramed BV · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  18. US 10752702

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  19. US 10752639

    Bridged bicyclic inhibitors of menin-MLL and methods of use

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  20. CA 3129357

    FORMULATIONS PHARMACEUTIQUES LIQUIDES DE CONJUGUES PTH

    ASCENDIS PHARMA BONE DISEASES AS [DK] · Granted Aug 20, 2020 · Expires Aug 15, 2040

    granted
  21. US 10745704

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  22. US 10745471

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  23. US 10744144

    Pharmaceutical formulation

    Semnur Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  24. US 10744230

    Biomimetic hybrid gel compositions and methods of use

    BIOACTIVE REGENERATIVE THERAPEUTICS, INC. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.